Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 10Unknown 7Not yet recruiting 6Completed 5Active not recruiting 4Terminated 2Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 629Prostatic Neoplasms 372Neoplasms 304Carcinoma, Non-Small-Cell Lung 216Lung Neoplasms 205Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 135Leukemia, Myeloid, Acute 129Neoplasm Metastasis 124Melanoma 116Brain Neoplasms 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 81Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66

Interventions

trastuzumab deruxtecan 1sintilimab 1pembrolizumab 1durvalumab 1cabozantinib 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Gastric Adenocarcinoma × Clear all
NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

National Cancer Center Hospital East

Phase 2 Active not recruiting
64 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 2 Active not recruiting
34 enrolled 11 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT06938139 2025-04-22

Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy

Fujian Medical University

Active not recruiting
90,000 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡